Gilead has chosen a partner for lenacapavir in the race to develop new low-frequency treatments for HIV. | Gilead has chosen ...

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results this Thursday after market close.

Gilead stock slumped late Thursday on soft product sales and lighter-than-expected revenue from its newcomer HIV prevention ...

Gilead Sciences has become the latest pharma to strengthen its in vivo cell therapy credentials this year, paying $350 million for CAR-T developer Interius BioTherapeutics. Integrating Interius into ...

Gilead is actively looking for late-stage and de-risked assets for potential deals across various therapeutic spaces, ...

Gilead Sciences (GILD) stock is in focus as the company fails in a late-stage trial which tested its Trodelvy cancer drug as ...

The death of a study volunteer further complicates the path forward for Intellia’s on-hold rare disease treatment. Elsewhere, Gilead reported a setback and J&J netted a first-of-its-kind approval.

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. Want to stay on top of ...

Dec 10 (Reuters) - Gilead Sciences Inc (GILD.O), opens new tab said on Thursday it will acquire MYR GmbH for about 1.15 billion euros ($1.39 billion) in cash, giving it access to the German biotech ...

Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

The biotechnology industry is split between two very different types of companies. On one side are the large, blue-chip leaders like Amgen Inc. (ticker: AMGN), Gilead Sciences Inc. (GILD), Vertex ...